Osteoporosis Drugs Market

Market Snapshot

A revised industry analysis on the osteoporosis drugs market by Persistence Market Research provides a detailed account of the landscape and predicts suitable forecasts.

From 2016 to 2020, the global osteoporosis drugs market exhibited a CAGR of 2.6%, and is expected to increase 1.3X over the forecast of 2021-2031. By the end of the decade, the industry is expected to be valued at approximately US$ 18 Bn. The North American market is valued at around US$ 4 Bn and holds 2/5 of the global market share.

Key Market Insights Provided in Osteoporosis Drugs Industry Survey:

• Market estimates and forecast 2016-2031
• Key drivers and restraints impacting market growth
• Segment-wise, country-wise, and region-wise analysis
• Competition mapping and benchmarking
• Brand share and market share analysis
• Key product innovations and regulatory climate
• COVID-19 Impact on sales of osteoporosis drugs and how to navigate
• Recommendation on key winning strategies

Research and Developments in Osteoporosis

Osteoporosis has become a common issue in recent times, and cases are rising as lifestyles become increasingly sedentary. As osteoporosis becomes a common issue, research & development for treatment drugs for this condition has also increased.

To make a stabilized human calcitonin, Purdue University created a prodrug form of the peptide hormone and increased its effectiveness as an osteoporosis treatment. Through this, researchers have improved the therapeutic benefits of human calcitonin.

Entera Bio recently announced some positive results from a bone mineral density study that it was conducting, which was in its second phase. EB613 is an oral formulation of human parathyroid hormone (1-34), which is expected to be the first oral bone building (anabolic) product to treat osteoporosis patients.

After the positive results of the 6-month long phase two study in 161 postmenopausal female subjects with osteoporosis, the study is expected to gain further impetus and develop a new breakthrough in the osteoporosis drugs industry.

Market Introduction

The global osteoporosis drugs market is projected to exhibit sluggish growth by the end of 2031 with escalating demand for these drugs across the globe for the treatment of ailments such as prophylaxis. The wide range of pipeline drugs are expected to create new revenue prospects in the market.

Growing osteoporosis conditions bred by the sedentary lifestyle is expected to drive the adoption rate of these drugs in the coming years.

Effect of COVID-19

The COVID-19 pandemic is expected to reduce demand for a brief time period owing to reduction in reported cases of ailments. The market is expected to witness a surge in demand with growing relaxations in people's movements.

North America is projected to hold major market share by the end of the forecast period owing to enhanced research & development activities and high medical standards.

Burgeoning investments are expected to impart a high growth rate to the osteoporosis market in the Asia Pacific, creating new revenue pockets to the manufacturers.

Market Players

The market players are adopting collaborative strategies to sustain market competition. The manufactures are investing in research and development to introduce innovative products in the market. Established players in the market include Novo Nordisk A/S, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., and Novartis AG.

Market Drivers

The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market.

However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits growth of the market.

The osteoporosis drugs market is anticipated to grow from an estimated US$ 12.5 Bn in 2021 to account for US$ 18 Bn by 2031, at a CAGR of 3.8%. North America is the largest market for osteoporosis drugs, with bisphosphonates being the most popular type of osteoporosis drugs. Asia-Pacific is the fastest growing region in terms of revenue while RANK ligand inhibitors are the fastest growing type of osteoporosis drugs.

Market Segmentation

This report provides in-depth analysis and estimation of the osteoporosis drugs market for 2021– 2031, considering 2020 as the base year for calculation. Moreover, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report.